कृपया अन्य खोज का प्रयास करें
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Alexis A. Borisy | 51 | 2011 | Co-Founder & Director |
Jeffrey W. Albers | 52 | 2014 | Chairman |
Kathryn Haviland | 47 | 2016 | President, CEO & Director |
Charles L. Sawyers | 64 | - | Member of Scientific Advisory Board |
Brian J. Druker | 68 | - | Member of Scientific Advisory Board |
William C. Hahn | - | - | Member of Scientific Advisory Board |
Nicholas B. Lydon | 67 | 2011 | Member of Scientific Advisory Board & Independent Director |
Mark A. Goldberg | 70 | 2015 | Independent Director |
George Daniel Demetri | 67 | 2012 | Chair of Scientific Advisory Board |
Lonnel Coats | 59 | 2016 | Independent Director |
Scott W. Lowe | - | - | Member of Scientific Advisory Board |
Habib Joseph Dable | 55 | 2022 | Independent Director |
Daniella Beckman | 45 | 2021 | Independent Director |
Lynn Seely | 65 | 2016 | Lead Independent Director |
John Tsai | 57 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है